103 results on '"Rayburn, Elizabeth R."'
Search Results
2. Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action
3. Anti-lung cancer effects of novel ginsenoside 25-OCH 3-PPD
4. Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible?
5. A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action
6. FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer
7. In vitro anti-cancer activity and structure–activity relationships of natural products isolated from fruits of Panax ginseng
8. Oncogenes as Novel Targets for Cancer Therapy (Part IV): Regulators of the Cell Cycle and Apoptosis
9. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway
10. Oncogenes as Novel Targets for Cancer Therapy (Part III): Transcription Factors
11. Oncogenes as Novel Targets for Cancer Therapy (Part II): Intermediate Signaling Molecules
12. Oncogenes as Novel Targets for Cancer Therapy (Part I): Growth Factors and Protein Tyrosine Kinases
13. Linkage between Toxicology of Drugs and Metabolism
14. Experimental Therapy of Prostate Cancer With Novel Natural Product Anti-cancer Ginsenosides
15. Experimental Therapy of Prostate Cancer With an Immunomodulatory Oligonucleotide: Effects on Tumor Growth, Apoptosis, Proliferation, and Potentiation of Chemotherapy
16. The need for contraception in patients taking prescription drugs: a review of FDA warning labels, duration of effects, and mechanisms of action
17. FDA-approved drugs that are spermatotoxic in animals and the utility of animal testing for human risk prediction
18. FDA-approved medications that impair human spermatogenesis
19. FDA-approved drugs that interfere with laboratory tests: A systematic search of US drug labels
20. FDA-approved drugs that interfere with laboratory tests: A systematic search of US drug labels.
21. KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology
22. Development and validation of an HPLC method for quantitation of BA-TPQ, a novel iminoquinone anticancer agent, and an initial pharmacokinetic study in mice
23. Preclinical Pharmacology of BA-TPQ, a Novel Synthetic Iminoquinone Anticancer Agent
24. Linkage Between Toxicology of Drugs and Metabolism
25. A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action
26. Anti-lung cancer effects of novel ginsenoside 25-OCH3-PPD
27. Novel ginsenosides 25-OH-PPD and 25-OCH 3 -PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action
28. In vitro and In vivo Anticancer Activity of Novel Synthetic Makaluvamine Analogues
29. FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer
30. RYBP stabilizes p53 by modulating MDM2
31. Extracellular Activity of Cyclic AMP–Dependent Protein Kinase as a Biomarker for Human Cancer Detection: Distribution Characteristics in a Normal Population and Cancer Patients
32. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy
33. Chemotherapy and chemosensitization of non–small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9
34. KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology.
35. Development and validation of an HPLC method for quantitation of BA-TPQ, a novel iminoquinone anticancer agent, and an initial pharmacokinetic study in mice.
36. Anti-lung cancer effects of novel ginsenoside 25-OCH3-PPD
37. Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action
38. RYBP stabilizes p53 by modulating MDM2.
39. In vitro anti-cancer activity and structure–activity relationships of natural products isolated from fruits of Panax ginseng.
40. Extracellular Activity of Cyclic AMP-Dependent Protein Kinase as a Biomarker for Human Cancer Detection: Distribution Characteristics in a Normal Population and Cancer Patients.
41. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway.
42. Oncogenes as Novel Targets for Cancer Therapy (Part IV): Regulators of the Cell Cycle and Apoptosis.
43. Oncogenes as Novel Targets for Cancer Therapy (Part III): Transcription Factors.
44. Oncogenes as Novel Targets for Cancer Therapy (Part II): Intermediate Signaling Molecules.
45. Oncogenes as Novel Targets for Cancer Therapy (Part I): Growth Factors and Protein Tyrosine Kinases.
46. FDA-approved medications that impair human spermatogenesis.
47. Recent advances in validating MDM2 as a cancer target.
48. Synthesis and in vitro anti-lung cancer activity of novel 1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogs.
49. Anti-Inflammatory Agents for Cancer Therapy.
50. Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.